Toll Free: 1-888-928-9744

Innovent Biologics, Inc. - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 28 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Innovent Biologics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Innovent Biologics, Inc. - Product Pipeline Review - 2015', provides an overview of the Innovent Biologics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Innovent Biologics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Innovent Biologics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Innovent Biologics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Innovent Biologics, Inc.'s pipeline products

Reasons to Buy

- Evaluate Innovent Biologics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Innovent Biologics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Innovent Biologics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Innovent Biologics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Innovent Biologics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Innovent Biologics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Innovent Biologics, Inc. Snapshot 5 Innovent Biologics, Inc. Overview 5 Key Information 5 Key Facts 5 Innovent Biologics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Innovent Biologics, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Innovent Biologics, Inc. - Pipeline Products Glance 12 Innovent Biologics, Inc. - Early Stage Pipeline Products 12 IND/CTA Filed Products/Combination Treatment Modalities 12 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Innovent Biologics, Inc. - Drug Profiles 15 rituximab biosimilar 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 adalimumab biosimilar 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 bevacizumab biosimilar 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 IBI-302 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 IBI-306 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 IBI-308 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Innovent Biologics, Inc. - Pipeline Analysis 21 Innovent Biologics, Inc. - Pipeline Products by Target 21 Innovent Biologics, Inc. - Pipeline Products by Route of Administration 22 Innovent Biologics, Inc. - Pipeline Products by Molecule Type 23 Innovent Biologics, Inc. - Pipeline Products by Mechanism of Action 24 Innovent Biologics, Inc. - Recent Pipeline Updates 25 Innovent Biologics, Inc. - Locations And Subsidiaries 26 Head Office 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 27 Disclaimer 28
List of Tables
Innovent Biologics, Inc., Key Information 5 Innovent Biologics, Inc., Key Facts 5 Innovent Biologics, Inc. - Pipeline by Indication, 2015 7 Innovent Biologics, Inc. - Pipeline by Stage of Development, 2015 8 Innovent Biologics, Inc. - Monotherapy Products in Pipeline, 2015 9 Innovent Biologics, Inc. - Partnered Products in Pipeline, 2015 10 Innovent Biologics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11 Innovent Biologics, Inc. - IND/CTA Filed, 2015 12 Innovent Biologics, Inc. - Preclinical, 2015 13 Innovent Biologics, Inc. - Discovery, 2015 14 Innovent Biologics, Inc. - Pipeline by Target, 2015 21 Innovent Biologics, Inc. - Pipeline by Route of Administration, 2015 22 Innovent Biologics, Inc. - Pipeline by Molecule Type, 2015 23 Innovent Biologics, Inc. - Pipeline Products by Mechanism of Action, 2015 24 Innovent Biologics, Inc. - Recent Pipeline Updates, 2015 25



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify